- Previous Close
144.62 - Open
143.69 - Bid 148.95 x 200
- Ask 149.56 x 200
- Day's Range
143.12 - 149.67 - 52 Week Range
85.29 - 161.00 - Volume
499,154 - Avg. Volume
588,336 - Market Cap (intraday)
8.923B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-9.63 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
198.23
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ascendispharma.comRecent News: ASND
View More
Performance Overview: ASND
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASND
View MoreValuation Measures
Market Cap
8.92B
Enterprise Value
9.39B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.89
Price/Book (mrq)
--
Enterprise Value/Revenue
26.45
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-154.12%
Return on Assets (ttm)
-27.92%
Return on Equity (ttm)
--
Revenue (ttm)
317.63M
Net Income Avi to Common (ttm)
-489.52M
Diluted EPS (ttm)
-9.63
Balance Sheet and Cash Flow
Total Cash (mrq)
258.7M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-104.13M
Research Analysis: ASND
View MoreCompany Insights: ASND
ASND does not have Company Insights